Ramipril Concept

subject area of

• A population‐based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors  Journal Articles
• Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials  Journal Articles
• Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials  Journal Articles
• Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes  Journal Articles
• Albuminuria and Rapid Loss of GFR and Risk of New Hip and Pelvic Fractures  Journal Articles
• Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)  Journal Articles
• Angiotensin Converting Enzyme Inhibitor Dialyzability and Outcomes in Older Patients Receiving Hemodialysis  Journal Articles
• Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries  Journal Articles
• Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)  Journal Articles
• Blood pressure and cardiovascular risk in the HOPE study  Journal Articles
• Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies  Journal Articles
• Blood-pressure reduction and cardiovascular risk in HOPE study  Journal Articles
• Cardiovascular Risk in Patients with Early Renal Insufficiency  Journal Articles
• Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk  Journal Articles
• Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk  Journal Articles
• Clinical decision making and the expected value of information  Journal Articles
• Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) Study  Journal Articles
• Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures  Journal Articles
• Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study  Journal Articles
• Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases  Journal Articles
• Coronary artery disease - Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study  Journal Articles
• Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study  Journal Articles
• Development of Renal Disease in People at High Cardiovascular Risk  Journal Articles
• Diabetes and the HOPE study: implications for macrovascular and microvascular disease.  Journal Articles
• Diet and Kidney Disease in High-Risk Individuals With Type 2 Diabetes Mellitus  Journal Articles
• Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies  Journal Articles
• Dysglycemia and a History of Reproductive Risk Factors  Journal Articles
• Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose  Journal Articles
• Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction  Journal Articles
• Effect of Ramipril on Cardiovascular Events in High-Risk Patients  Journal Articles
• Effect of Ramipril on the Incidence of Diabetes  Journal Articles
• Effect of Ramipril on the Incidence of Diabetes  Journal Articles
• Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose  Journal Articles
• Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: The Ramipril C-Reactive pRotein Randomized evaluation (4R) trial results  Journal Articles
• Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients  Journal Articles
• Effect of long-term therapy with ramipril in high-risk women  Journal Articles
• Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial  Journal Articles
• Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose  Journal Articles
• Effects of Ramipril and Vitamin E on Atherosclerosis  Journal Articles
• Effects of Ramipril on Coronary Events in High-Risk Persons  Journal Articles
• Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease  Journal Articles
• Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial  Journal Articles
• Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients  Journal Articles
• Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial  Journal Articles
• Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease  Journal Articles
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy  Journal Articles
• Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction  Journal Articles
• Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both  Journal Articles
• From the hope to the ontarget and the transcend studies: challenges in improving prognosis  Journal Articles
• Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema  Journal Articles
• Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk  Journal Articles
• Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: Results from the ONTARGET/TRANSCEND Research Programme  Journal Articles
• Impact of Ramipril on the Circadian Periodicity of Acute Myocardial Infarction  Journal Articles
• Impact of Sex on Cardiovascular Outcome in Patients at High Cardiovascular Risk  Journal Articles
• Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial  Journal Articles
• Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease  Journal Articles
• Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study  Journal Articles
• In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events  Journal Articles
• Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal  Journal Articles
• Is therapy of people with chronic kidney disease ONTARGET?  Journal Articles
• Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])  Journal Articles
• Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes  Journal Articles
• Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes  Journal Articles
• Modifying the natural history of atherosclerosis: the SECURE trial.  Journal Articles
• More than just hype.  Journal Articles
• Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice  Journal Articles
• Preventing stroke with ramipril---authors' reply  Journal Articles
• Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study  Journal Articles
• Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study  Journal Articles
• Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study  Journal Articles
• Ramipril and Risk of Diabetes—Reply  Journal Articles
• Ramipril and the Development of Diabetes  Journal Articles
• Ramipril in the treatment of vascular diseases  Journal Articles
• Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study  Journal Articles
• Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.  Journal Articles
• Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial  Journal Articles
• Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials  Journal Articles
• Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril  Journal Articles
• Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE  Journal Articles
• Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients  Journal Articles
• Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial  Journal Articles
• Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial  Journal Articles
• Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies  Journal Articles
• Role of Renin-Angiotensin System Blockade in Patients With Diabetes Mellitus  Journal Articles
• Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes  Journal Articles
• Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE Study  Journal Articles
• Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: Substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND)  Journal Articles
• Study Design and Baseline Characteristics of the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E: SECURE**This study was supported by Research Grant Ul-12363 from the Medicine Research Council of Canada, Ottawa; and by Hoechst Marion Roussel, Laval, Canada, Inc.  Journal Articles
• Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk  Journal Articles
• Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease  Journal Articles
• Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events  Journal Articles
• Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.  Journal Articles
• The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences  Journal Articles
• The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.  Journal Articles
• The HOPE study and diabetes  Journal Articles
• The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct  Journal Articles
• The Mini‐Mental State Examination, Clinical Factors, and Motor Vehicle Crash Risk  Journal Articles
• The Prognostic Significance of Bundle Branch Block in High‐Risk Chronic Stable Vascular Disease Patients: A Report from the HOPE Trial  Journal Articles
• The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics  Journal Articles
• The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study  Journal Articles
• The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial  Journal Articles
• The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study  Journal Articles
• The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis  Journal Articles
• Use of ramipril in preventing stroke: double blind randomised trial  Journal Articles
• Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study  Journal Articles